Diabetic kidney disease: act now or pay later
暂无分享,去创建一个
[1] M. Woodward,et al. Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes , 2009, Diabetes Care.
[2] Mark Woodward,et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.
[3] G. Bakris,et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] G. Bakris,et al. Novel therapies of diabetic nephropathy , 2009, Current opinion in nephrology and hypertension.
[5] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[6] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[7] R. Bilous,et al. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[8] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[9] O. Pedersen,et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.
[10] J. Shaw,et al. Limited knowledge of kidney disease in a survey of AusDiab study participants , 2008, The Medical journal of Australia.
[11] Merlin C. Thomas,et al. Screening for chronic kidney disease in patients with diabetes: are we missing the point? , 2008, Nature Clinical Practice Nephrology.
[12] K. Iseki,et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening , 2008, Clinical and Experimental Nephrology.
[13] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[14] Ho-Young Son,et al. Epidemic obesity and type 2 diabetes in Asia , 2006, The Lancet.
[15] H. Parving,et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. , 2006, Kidney international.
[16] M. Mauer,et al. Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.
[17] Rury R Holman,et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.
[18] Robert Atkins,et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. , 2002, Diabetes care.
[19] Michael J Lysaght,et al. Maintenance dialysis population dynamics: current trends and long-term implications. , 2002, Journal of the American Society of Nephrology : JASN.
[20] J. Shaw,et al. Global and societal implications of the diabetes epidemic , 2001, Nature.
[21] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[22] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[23] H. King,et al. Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.